Prognostic factors for overall survival in castration-resistant metastatic prostate cancer treated with docetaxel (MeProCSS): results from a German real-world cohort

To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).

Saved in:

Bibliographic Details
Main Authors:	Steffens, Felix (Author) , Wessels, Frederik (Author) , Hetjens, Svetlana (Author) , Carl, Nicolas (Author) , Nitschke, Katja (Author) , Uysal, Daniel (Author) , Moharam, Nadim (Author) , Patroi, Paul (Author) , Worst, Thomas (Author) , Kowalewski, Karl-Friedrich (Author) , Michel, Maurice Stephan (Author) , Neuberger, Manuel (Author)
Format:	Article (Journal)
Language:	English
Published:	27 January 2025
In:	International urology and nephrology Year: 2025, Volume: 57, Issue: 7, Pages: 2063-2072
ISSN:	1573-2584
DOI:	10.1007/s11255-025-04389-2
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1007/s11255-025-04389-2
Author Notes:	Felix Steffens, Frederik Wessels, Svetlana Hetjens, Nicolas Carl, Katja Nitschke, Daniel Uysal, Nadim Moharam, Paul Patroi, Thomas Stefan Worst, Karl Friedrich Kowalewski, Maurice Stephan Michel, Manuel Neuberger

Description
Summary:	To identify prognostic factors for overall survival (OS) and develop a prognostic score in patients receiving docetaxel in metastatic castration-resistant prostate cancer (mCRPC).
Item Description:	Gesehen am 23.07.2025
Physical Description:	Online Resource
ISSN:	1573-2584
DOI:	10.1007/s11255-025-04389-2